Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
500 CHF | +194,12% | -.--% | -.--% |
09:57 | Kenvue fixe le prix de l'offre secondaire d'actions ordinaires | MT |
14/05 | Transcript : Johnson & Johnson Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM |
CA 2024 * | 88,37 Md 79,73 Md | CA 2025 * | 90,78 Md 81,91 Md | Capitalisation | 364 Md 329 Md |
---|---|---|---|---|---|
Résultat net 2024 * | 22,04 Md 19,88 Md | Résultat net 2025 * | 23,09 Md 20,83 Md | VE / CA 2024 * | 4,04 x |
Trésorerie nette 2024 * | 7 Md 6,31 Md | Trésorerie nette 2025 * | 21,07 Md 19,01 Md | VE / CA 2025 * | 3,78 x |
PER 2024 * |
16,8
x | PER 2025 * |
15,9
x | Employés | - |
Rendement 2024 * |
3,19% | Rendement 2025 * |
3,33% | Flottant | 77,08% |
Dernier transcript sur Johnson & Johnson
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01/01/89 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01/01/98 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/11/19 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 19/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22/10/09 |
Nom | PEA | Position | Varia. 1 janv. | Notation |
---|---|---|---|---|
AXA ACT CARBON OFFSET EQUITY QI C | Non | 9.07M EUR | +8,00% | |
COMGEST GROWTH GLOBAL USD ACC | Non | 38.75M USD | +22,00% | |
AXA IM GLOBAL EQUITY QI B EUR ACC | Non | 7.95M EUR | +17,00% | |
AXA AMÉRIQUE ACTIONS AC | Non | 1.54M EUR | +15,00% | |
COMGEST GROWTH AMERICA USD ACC | Non | 31.29M USD | +29,00% |
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+31,37% | 588 Md | |
+20,83% | 326 Md | |
+5,69% | 285 Md | |
+14,83% | 239 Md | |
+9,93% | 210 Md | |
-6,95% | 200 Md | |
+10,77% | 167 Md | |
+0,10% | 161 Md | |
+0,89% | 124 Md |
- Bourse
- Actions
- Action JNJ
- Action JNJ